Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.

Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JGF, Damman K, Redon J, Coats AJS; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2019 Dec 10;74(23):2893-2904. doi: 10.1016/j.jacc.2019.09.059.

2.

Glycaemic control and excess risk of major coronary events in patients with type 2 diabetes: a population-based study.

Tancredi M, Rosengren A, Svensson AM, Pivodic A, Gudbjörnsdottir S, Wedel H, Lind M.

Open Heart. 2019 Sep 9;6(2):e000967. doi: 10.1136/openhrt-2018-000967. eCollection 2019.

3.

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Koomen JV, Heerspink HJL, Schrieks IC, Schwartz GG, Lincoff AM, Nicholls SJ, Svensson A, Wedel H, Weichert A, Grobbee DE, Stevens J.

Diabetes Obes Metab. 2020 Jan;22(1):30-38. doi: 10.1111/dom.13862. Epub 2019 Oct 1.

4.

HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study.

Lind M, Pivodic A, Svensson AM, Ólafsdóttir AF, Wedel H, Ludvigsson J.

BMJ. 2019 Aug 28;366:l4894. doi: 10.1136/bmj.l4894.

5.

Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.

Postma W, Fabris E, Van der Ent M, Hermanides R, Buszman P, Von Birgelen C C, Cook S, Wedel H, De Luca G, Delewi R, Zijlstra F, Kedhi E.

Catheter Cardiovasc Interv. 2019 Jul 3. doi: 10.1002/ccd.28376. [Epub ahead of print]

PMID:
31268629
6.

Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes.

Ólafsdóttir AF, Svensson AM, Pivodic A, Gudbjörnsdottir S, Nyström T, Wedel H, Rosengren A, Lind M.

BMJ Open Diabetes Res Care. 2019 Apr 14;7(1):e000602. doi: 10.1136/bmjdrc-2018-000602. eCollection 2019.

7.

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F.

BMJ. 2018 Oct 2;363:k3793. doi: 10.1136/bmj.k3793.

8.

Fracture Risk After Gastric Bypass Surgery: A Retrospective Cohort Study.

Axelsson KF, Werling M, Eliasson B, Szabo E, Näslund I, Wedel H, Lundh D, Lorentzon M.

J Bone Miner Res. 2018 Dec;33(12):2122-2131. doi: 10.1002/jbmr.3553. Epub 2018 Aug 13.

9.

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.

Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG.

Diabetes Care. 2018 Aug;41(8):1792-1800. doi: 10.2337/dc18-0158. Epub 2018 Jun 14.

10.

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.

Stähli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Rydén L, Svensson A, Wedel H, Weichert A, Lincoff AM, Grobbee DE, Tardif JC, Schwartz GG.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2522-2533. doi: 10.1210/jc.2017-02772.

11.

A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3).

Ólafsdóttir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, Nyström T, Wijkman M, Schwarcz E, Hellman J, Heise T, Lind M.

Diabetes Technol Ther. 2018 Apr;20(4):274-284. doi: 10.1089/dia.2017.0363. Epub 2018 Apr 2.

12.

Lung transplantation after allogeneic stem cell transplantation: a pan-European experience.

Greer M, Berastegui C, Jaksch P, Benden C, Aubert J, Roux A, Lhuillier E, Hirschi S, Reynaud-Gaubert M, Philit F, Claustre J, LePalud P, Stern M, Knoop C, Vos R, Verschuuren E, Fisher A, Riise G, Hansson L, Iversen M, Hämmäinen P, Wedel H, Smits J, Gottlieb J, Holm AM.

Eur Respir J. 2018 Feb 14;51(2). pii: 1701330. doi: 10.1183/13993003.01330-2017. Print 2018 Feb.

13.

Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry.

Angerås O, Haraldsson I, Redfors B, Fröbert O, Petursson P, Albertsson P, Ioanes D, Odenstedt J, Olsson H, Witt N, Rück A, Millgård J, Nilsson J, Persson J, Söderbom M, Wedel H, Erlinge D, James S, Råmunddal T, Omerovic E.

J Am Heart Assoc. 2018 Jan 9;7(1). pii: e007680. doi: 10.1161/JAHA.117.007680.

14.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.

Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group.

Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.

15.

Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study.

Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, Svensson AM, Lind M.

Lancet Diabetes Endocrinol. 2017 Oct;5(10):799-807. doi: 10.1016/S2213-8587(17)30262-0. Epub 2017 Aug 30.

PMID:
28838683
16.

Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes.

Matuleviciene-Anängen V, Rosengren A, Svensson AM, Pivodic A, Gudbjörnsdottir S, Wedel H, Kosiborod M, Haraldsson B, Lind M.

Heart. 2017 Nov;103(21):1687-1695. doi: 10.1136/heartjnl-2016-311050. Epub 2017 Jul 14.

PMID:
28710186
17.

Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.

Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M.

JAMA. 2017 Jul 11;318(2):146-155. doi: 10.1001/jama.2017.8040.

18.

A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".

Kedhi E, Fabris E, van der Ent M, Kennedy MW, Buszman P, von Birgelen C, Cook S, Wedel H, Zijlstra F.

Am Heart J. 2017 Jun;188:11-17. doi: 10.1016/j.ahj.2017.02.018. Epub 2017 Feb 20.

PMID:
28577666
19.

Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.

Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2017 Jun 20;69(24):2885-2896. doi: 10.1016/j.jacc.2017.04.001. Epub 2017 Apr 30. Review.

20.

Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.

Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, Schwarz E, Ólafsdóttir AF, Frid A, Wedel H, Ahlén E, Nyström T, Hellman J.

JAMA. 2017 Jan 24;317(4):379-387. doi: 10.1001/jama.2016.19976. Erratum in: JAMA. 2017 May 9;317(18):1912.

PMID:
28118454
21.

A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: A randomised controlled trial.

Hellgren MI, Jansson PA, Wedel H, Lindblad U.

Scand J Public Health. 2016 Nov;44(7):718-725. doi: 10.1177/1403494816663539. Epub 2016 Aug 22.

PMID:
27550085
22.

Prognostic Impact of Chronic Total Occlusions: A Report From SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Råmunddal T, Hoebers LP, Henriques JP, Dworeck C, Angerås O, Odenstedt J, Ioanes D, Olivecrona G, Harnek J, Jensen U, Aasa M, Albertsson P, Wedel H, Omerovic E.

JACC Cardiovasc Interv. 2016 Aug 8;9(15):1535-44. doi: 10.1016/j.jcin.2016.04.031.

23.

Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes.

Ahlén E, Pivodic A, Wedel H, Dahlqvist S, Kosiborod M, Lind M.

J Diabetes Sci Technol. 2016 Aug 22;10(5):1006-14. doi: 10.1177/1932296816652901. Print 2016 Sep.

24.

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis.

Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, Cleland JG, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GY, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

BMJ. 2016 Apr 20;353:i1855. doi: 10.1136/bmj.i1855. Review.

25.

Excess Mortality among Persons with Type 2 Diabetes.

Lind M, Wedel H, Rosengren A.

N Engl J Med. 2016 Feb 25;374(8):788-9. doi: 10.1056/NEJMc1515130. No abstract available.

PMID:
26933853
26.

Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.

Damman K, Kjekshus J, Wikstrand J, Cleland JG, Komajda M, Wedel H, Waagstein F, McMurray JJ.

Eur J Heart Fail. 2016 Mar;18(3):328-36. doi: 10.1002/ejhf.462. Epub 2015 Dec 23.

27.

Excess Mortality among Persons with Type 2 Diabetes.

Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M.

N Engl J Med. 2015 Oct 29;373(18):1720-32. doi: 10.1056/NEJMoa1504347.

28.

The Swedish CArdioPulmonary BioImage Study: objectives and design.

Bergström G, Berglund G, Blomberg A, Brandberg J, Engström G, Engvall J, Eriksson M, de Faire U, Flinck A, Hansson MG, Hedblad B, Hjelmgren O, Janson C, Jernberg T, Johnsson Å, Johansson L, Lind L, Löfdahl CG, Melander O, Östgren CJ, Persson A, Persson M, Sandström A, Schmidt C, Söderberg S, Sundström J, Toren K, Waldenström A, Wedel H, Vikgren J, Fagerberg B, Rosengren A.

J Intern Med. 2015 Dec;278(6):645-59. doi: 10.1111/joim.12384. Epub 2015 Jun 19.

29.

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.

Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M.

Am Heart J. 2015 Jul;170(1):117-22. doi: 10.1016/j.ahj.2015.03.021. Epub 2015 Apr 2.

PMID:
26093872
30.

Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.

Kristensen SL, Jhund PS, Køber L, Preiss D, Kjekshus J, McKelvie RS, Zile MR, Anand IS, Wikstrand J, Wedel H, Komajda M, Carson PE, Cleland JG, McMurray JJ.

Eur J Heart Fail. 2015 Feb;17(2):169-76. doi: 10.1002/ejhf.211. Epub 2014 Dec 30.

31.

Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA).

Haver VG, Mateo Leach I, Kjekshus J, Fox JC, Wedel H, Wikstrand J, de Boer RA, van Gilst WH, McMurray JJ, van Veldhuisen DJ, van der Harst P.

Eur J Heart Fail. 2015 Mar;17(3):313-9. doi: 10.1002/ejhf.237. Epub 2015 Feb 2.

32.

Low socioeconomic status of a patient's residential area is associated with worse prognosis after acute myocardial infarction in Sweden.

Bergström G, Redfors B, Angerås O, Dworeck C, Shao Y, Haraldsson I, Petursson P, Milicic D, Wedel H, Albertsson P, Råmunddal T, Rosengren A, Omerovic E.

Int J Cardiol. 2015 Mar 1;182:141-7. doi: 10.1016/j.ijcard.2014.12.060. Epub 2014 Dec 23.

PMID:
25577750
33.

The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA).

Haver VG, Verweij N, Kjekshus J, Fox JC, Wedel H, Wikstrand J, van Gilst WH, de Boer RA, van Veldhuisen DJ, van der Harst P.

BMC Med Genet. 2014 Dec 21;15:140. doi: 10.1186/s12881-014-0140-3.

34.

Glycemic control and excess mortality in type 1 diabetes.

Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A.

N Engl J Med. 2014 Nov 20;371(21):1972-82. doi: 10.1056/NEJMoa1408214.

35.

International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.

Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M, Carson PE, Pfeffer MA, Swedberg K, Wedel H, Yusuf S, McMurray JJ.

Circulation. 2015 Jan 6;131(1):43-53. doi: 10.1161/CIRCULATIONAHA.114.012284. Epub 2014 Nov 18.

PMID:
25406306
36.

Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Badar AA, Perez-Moreno AC, Jhund PS, Wong CM, Hawkins NM, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, Wedel H, Watkins S, Gardner RS, Petrie MC, McMurray JJ.

Eur Heart J. 2014 Dec 21;35(48):3426-33. doi: 10.1093/eurheartj/ehu342. Epub 2014 Sep 28.

PMID:
25265976
37.

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.

Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

Lancet. 2014 Dec 20;384(9961):2235-43. doi: 10.1016/S0140-6736(14)61373-8. Epub 2014 Sep 2.

PMID:
25193873
38.

Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).

Rogers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ.

JACC Heart Fail. 2014 Jun;2(3):289-97. doi: 10.1016/j.jchf.2013.12.007. Epub 2014 Apr 30.

39.

Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.

Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM.

JAMA. 2014 Jun 11;311(22):2297-304. doi: 10.1001/jama.2014.5988.

PMID:
24915261
40.

Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: A pilot study.

Hellgren MI, Petzold M, Beteus-Forslund H, Wedel H, Jansson PA, Lindblad U.

Scand J Public Health. 2014 Jul;42(5):463-70. doi: 10.1177/1403494814528290. Epub 2014 May 27.

PMID:
24867622
41.

Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.

Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A.

Lancet Diabetes Endocrinol. 2014 Aug;2(8):627-33. doi: 10.1016/S2213-8587(14)70088-9. Epub 2014 May 13.

PMID:
24831989
42.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
43.
44.

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE.

Am Heart J. 2013 Sep;166(3):429-34. doi: 10.1016/j.ahj.2013.05.013. Epub 2013 Jul 26.

PMID:
24016490
45.

Alcohol consumption and alcohol problems after bariatric surgery in the Swedish obese subjects study.

Svensson PA, Anveden Å, Romeo S, Peltonen M, Ahlin S, Burza MA, Carlsson B, Jacobson P, Lindroos AK, Lönroth H, Maglio C, Näslund I, Sjöholm K, Wedel H, Söderpalm B, Sjöström L, Carlsson LM.

Obesity (Silver Spring). 2013 Dec;21(12):2444-51. doi: 10.1002/oby.20397. Epub 2013 May 31.

46.

ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data.

Prieto-Merino D, Dobson J, Gupta AK, Chang CL, Sever PS, Dahlöf B, Wedel H, Pocock S, Poulter N; ASCOT-BPLA Investigators.

J Hum Hypertens. 2013 Aug;27(8):492-6. doi: 10.1038/jhh.2013.3. Epub 2013 Feb 14.

PMID:
23407372
47.

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial.

Mellbin LG, Malmberg K, Rydén L, Wedel H, Vestberg D, Lind M.

Eur Heart J. 2013 Feb;34(5):374-9. doi: 10.1093/eurheartj/ehs384. Epub 2012 Nov 9.

PMID:
23144046
48.

Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.

Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, Jacobson P, Lönroth H, Maglio C, Näslund I, Pirazzi C, Romeo S, Sjöholm K, Sjöström E, Wedel H, Svensson PA, Sjöström L.

N Engl J Med. 2012 Aug 23;367(8):695-704. doi: 10.1056/NEJMoa1112082.

49.

Feasibility of the FINDRISC questionnaire to identify individuals with impaired glucose tolerance in Swedish primary care. A cross-sectional population-based study.

Hellgren MI, Petzold M, Björkelund C, Wedel H, Jansson PA, Lindblad U.

Diabet Med. 2012 Dec;29(12):1501-5. doi: 10.1111/j.1464-5491.2012.03664.x.

PMID:
22443428
50.

Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

Zannad F, Stough WG, Pocock SJ, Sleight P, Cushman WC, Cleland JG, McMurray JJ, Lonn E, Geller NL, Wedel H, Abadie E, Alonso-Garcia A, Pitt B.

Eur Heart J. 2012 May;33(9):1049-57. doi: 10.1093/eurheartj/ehr437. Epub 2012 Mar 15. Review.

PMID:
22422830

Supplemental Content

Support Center